Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Etrumadenant||AB 928|AB-928|AB928||Adenosine Targeting 22||Etrumadenant is an antagonist of the adenosine receptors, A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15, PMID: 30569245).|
|IPI-549||IPI 549|IPI549||PIK3CG inhibitor 9||IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029, PMID: 32194211).|
|Pegylated liposomal doxorubicin||Doxil||ATI-0918|CAELYX|liposomal doxorubicin||Chemotherapy - Anthracycline 13||Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03719326||Phase I||Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin Etrumadenant + Pegylated liposomal doxorubicin||A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies||Completed||USA||1|